PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19947891-3 2010 This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports that co-administration of P-glycoprotein inhibitors has altered the stereoselective pharmacokinetics of fexofenadine enantiomers. fexofenadine 61-73 ATP binding cassette subfamily B member 1 Homo sapiens 158-172 19947891-3 2010 This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports that co-administration of P-glycoprotein inhibitors has altered the stereoselective pharmacokinetics of fexofenadine enantiomers. fexofenadine 236-248 ATP binding cassette subfamily B member 1 Homo sapiens 158-172 19947891-7 2010 Co-administration of itraconazole and/or verapamil significantly increased the AUC(0 - 24) of both enantiomers; their influence on the P-glycoprotein-mediated transport of (S)-fexofenadine was greater than that of the (R)-enantiomer. fexofenadine 172-188 ATP binding cassette subfamily B member 1 Homo sapiens 135-149 19947891-8 2010 However, because t(max) and t(1/2) were constant in both studies, the fexofenadine stereoselective pharmacokinetics appears to be due to P-glycoprotein efflux activity in the small intestine, which suggests that P-glycoprotein probably possesses the chiral discriminatory abilities. fexofenadine 70-82 ATP binding cassette subfamily B member 1 Homo sapiens 137-151 19947891-8 2010 However, because t(max) and t(1/2) were constant in both studies, the fexofenadine stereoselective pharmacokinetics appears to be due to P-glycoprotein efflux activity in the small intestine, which suggests that P-glycoprotein probably possesses the chiral discriminatory abilities. fexofenadine 70-82 ATP binding cassette subfamily B member 1 Homo sapiens 212-226 18570599-2 2008 We evaluated whether a genetic polymorphism of multi-drug resistance 1 gene (MDR1) could produce variations in pharmacokinetic and pharmacodynamic parameters of fexofenadine. fexofenadine 161-173 ATP binding cassette subfamily B member 1 Homo sapiens 47-70 19204737-8 2009 Coculture with fexofenadine(1 microM), an MDR1 substrate known to rescue misfolding in other membrane proteins, restored cell surface expression of MDR1 G2677T/C3435T and restored resistance to block HERG by ibutilide 200 nM (98.5+/-0.98% vs 42.3+/-2.2%, P<0.001). fexofenadine 15-27 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 19204737-8 2009 Coculture with fexofenadine(1 microM), an MDR1 substrate known to rescue misfolding in other membrane proteins, restored cell surface expression of MDR1 G2677T/C3435T and restored resistance to block HERG by ibutilide 200 nM (98.5+/-0.98% vs 42.3+/-2.2%, P<0.001). fexofenadine 15-27 ATP binding cassette subfamily B member 1 Homo sapiens 148-152 19204737-9 2009 The non-synonymous MDR1 variant G2677 T (A893S) confers resistance to ibutilide block of I(Kr), which is mitigated by the C3435T polymorphism through reduced protein expression, an effect that can be restored by coculture with fexofenadine. fexofenadine 227-239 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 19552748-9 2009 CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. fexofenadine 88-100 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 19552748-9 2009 CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. fexofenadine 88-100 ATP binding cassette subfamily B member 1 Homo sapiens 194-198 19552748-9 2009 CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. fexofenadine 149-161 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 19552748-9 2009 CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. fexofenadine 149-161 ATP binding cassette subfamily B member 1 Homo sapiens 194-198 19552748-9 2009 CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. fexofenadine 252-266 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 19552748-9 2009 CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. fexofenadine 252-266 ATP binding cassette subfamily B member 1 Homo sapiens 194-198 19238656-8 2008 Acute and steady-state ritonavir increased the fexofenadine AUC(0-infinity) 2.8- and 1.4-fold, respectively, suggesting P-gp inhibition. fexofenadine 47-59 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 19221726-0 2009 Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. fexofenadine 58-70 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 19221726-8 2009 CONCLUSION: The results of the present study showed that short-term use of quercetin elevated the plasma concentrations of fexofenadine, probably by the inhibition of P-gp-mediated efflux in humans. fexofenadine 123-135 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 19552748-0 2009 Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. fexofenadine 32-44 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 19552748-1 2009 AIMS: The aim was to compare possible effects of verapamil, as a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of each fexofenadine enantiomer, as a P-gp substrate. fexofenadine 130-142 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 19552748-1 2009 AIMS: The aim was to compare possible effects of verapamil, as a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of each fexofenadine enantiomer, as a P-gp substrate. fexofenadine 130-142 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 19552748-1 2009 AIMS: The aim was to compare possible effects of verapamil, as a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of each fexofenadine enantiomer, as a P-gp substrate. fexofenadine 130-142 ATP binding cassette subfamily B member 1 Homo sapiens 160-164 18511651-8 2008 ABCB1 3435 C/T carriers showed increased basal P-gp activity in CD4+ and CD8+ T cells, increased R123-induced efflux activity in CD4+ T cell, and decreased fexofenadine AUC. fexofenadine 156-168 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 18570599-2 2008 We evaluated whether a genetic polymorphism of multi-drug resistance 1 gene (MDR1) could produce variations in pharmacokinetic and pharmacodynamic parameters of fexofenadine. fexofenadine 161-173 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 17230498-1 2007 Fexofenadine, a substrate of P-glycoprotein and an organic anion transporter polypeptide, is commonly used to assess P-glycoprotein activity in vivo. fexofenadine 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 29-43 18294330-3 2008 WHAT THIS STUDY ADDS: This study indicates that the stereoselective pharmacokinetics of fexofenadine are due to P-gp-mediated transport and its stereoselectivity is altered by itraconazole, a an inhibitor of P-gp. fexofenadine 88-100 ATP binding cassette subfamily B member 1 Homo sapiens 112-116 18294330-3 2008 WHAT THIS STUDY ADDS: This study indicates that the stereoselective pharmacokinetics of fexofenadine are due to P-gp-mediated transport and its stereoselectivity is altered by itraconazole, a an inhibitor of P-gp. fexofenadine 88-100 ATP binding cassette subfamily B member 1 Homo sapiens 208-212 18294330-4 2008 AIMS: The aim of this study was to determine the inhibitory effect of itraconazole, a P-glycoprotein (P-gp) inhibitor, on the stereoselective pharmacokinetics of fexofenadine. fexofenadine 162-174 ATP binding cassette subfamily B member 1 Homo sapiens 86-100 18294330-4 2008 AIMS: The aim of this study was to determine the inhibitory effect of itraconazole, a P-glycoprotein (P-gp) inhibitor, on the stereoselective pharmacokinetics of fexofenadine. fexofenadine 162-174 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 18294330-11 2008 CONCLUSIONS: This study indicates that the stereoselective pharmacokinetics of fexofenadine are due to P-gp-mediated transport and its stereoselectivity is altered by itraconazole, a P-gp inhibitor. fexofenadine 79-91 ATP binding cassette subfamily B member 1 Homo sapiens 103-107 18294330-11 2008 CONCLUSIONS: This study indicates that the stereoselective pharmacokinetics of fexofenadine are due to P-gp-mediated transport and its stereoselectivity is altered by itraconazole, a P-gp inhibitor. fexofenadine 79-91 ATP binding cassette subfamily B member 1 Homo sapiens 183-187 17230498-1 2007 Fexofenadine, a substrate of P-glycoprotein and an organic anion transporter polypeptide, is commonly used to assess P-glycoprotein activity in vivo. fexofenadine 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 17230498-9 2007 Fexofenadine is transported by both P-glycoprotein and OATP and is not metabolized by intestinal CYP3A. fexofenadine 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 17230498-10 2007 Our findings suggest that the affinity of P-glycoprotein for S(-)-fexofenadine is greater than its affinity for the R(+)-enantiomer. fexofenadine 62-78 ATP binding cassette subfamily B member 1 Homo sapiens 42-56 15312146-11 2004 Fexofenadine is a P-glycoprotein (P-gp) substrate and P-gp is certainly involved both in the poor brain penetration by the compound and, at least partially, in a number of observed drug interactions. fexofenadine 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 16964701-3 2006 Between them, polymorphisms of MDR1 gene coding trans-membrane transport glicoprotein P-gp have been reported to affect the outcome of therapy, and was studied for different drugs-digoxin, fexofenadine, etoposid, vincristine, vinblastine, athracyclines and taxans. fexofenadine 189-201 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 15536457-0 2004 A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. fexofenadine 48-60 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 15536457-3 2004 This study was performed to clarify the effects of major MDR1 gene polymorphisms, including a variant A allele in exon 21, on fexofenadine pharmacokinetics. fexofenadine 126-138 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 15536457-5 2004 A single oral dose of 180 mg fexofenadine hydrochloride was administered to 33 healthy Korean male volunteers, who were divided into 6 groups based on the MDR1 genotype for the G2677T/A polymorphism in exon 21 and the C3435T polymorphism in exon 26. fexofenadine 29-55 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 15312146-11 2004 Fexofenadine is a P-glycoprotein (P-gp) substrate and P-gp is certainly involved both in the poor brain penetration by the compound and, at least partially, in a number of observed drug interactions. fexofenadine 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 15359574-7 2004 All four P-gp inhibitors had a strong, concentration-dependent effect on the Papp of fexofenadine in both directions, with GF 120918 being the most specific among them. fexofenadine 85-97 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 15359574-8 2004 The IC50 of verapamil was 8.44 microM on the P-gp-mediated secretion of fexofenadine. fexofenadine 72-84 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 15359574-10 2004 CONCLUSIONS: This study clearly indicates that P-gp was the main transport protein of fexofenadine in the Caco-2 model. fexofenadine 86-98 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 15217301-6 2004 With regard to the variability, polymorphisms of the MDR1 gene have recently been reported to be associated with alterations in disposition kinetics and interaction profiles of clinically useful drugs, including digoxin, fexofenadine, ciclosporin and talinolol. fexofenadine 221-233 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 15125696-0 2004 Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates. fexofenadine 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 15125696-2 2004 Several studies have shown P-glycoprotein is involved in the absorption and excretion of fexofenadine. fexofenadine 89-101 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 15125696-8 2004 In addition, the effect of fexofenadine on P-glycoprotein function was examined by flow cytometry using rhodamine 123 and CD56-positive lymphocytes. fexofenadine 27-39 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 10421612-0 1999 OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. fexofenadine 82-94 ATP binding cassette subfamily B member 1 Homo sapiens 9-23 14586383-14 2003 The most plausible mechanism is either decreased organic anion transporting polypeptide-mediated sinusoidal uptake or P-glycoprotein-mediated canalicular secretion of fexofenadine, or both. fexofenadine 167-179 ATP binding cassette subfamily B member 1 Homo sapiens 118-132 12087344-4 2002 Fexofenadine, 60 mg, was administered orally before administration of St John"s wort, with a single dose of St John"s wort (900 mg), and after 2 weeks of treatment with St John"s wort (300 mg 3 times a day) to determine P-glycoprotein activity. fexofenadine 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 220-234 11994059-0 2002 MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. fexofenadine 72-84 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 11994059-0 2002 MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. fexofenadine 72-84 ATP binding cassette subfamily B member 1 Homo sapiens 47-61 11503014-7 2001 In humans, MDR1*1 and MDR1*2 variants were associated with differences in fexofenadine levels, consistent with the in vitro data, with the area under the plasma level-time curve being almost 40% greater in the *1/*1 genotype compared with the *2/*2 and the *1/*2 heterozygotes having an intermediate value, suggesting enhanced in vivo P-glycoprotein activity among subjects with the MDR1*2 allele. fexofenadine 74-86 ATP binding cassette subfamily B member 1 Homo sapiens 11-15 11503014-7 2001 In humans, MDR1*1 and MDR1*2 variants were associated with differences in fexofenadine levels, consistent with the in vitro data, with the area under the plasma level-time curve being almost 40% greater in the *1/*1 genotype compared with the *2/*2 and the *1/*2 heterozygotes having an intermediate value, suggesting enhanced in vivo P-glycoprotein activity among subjects with the MDR1*2 allele. fexofenadine 74-86 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 11503014-7 2001 In humans, MDR1*1 and MDR1*2 variants were associated with differences in fexofenadine levels, consistent with the in vitro data, with the area under the plasma level-time curve being almost 40% greater in the *1/*1 genotype compared with the *2/*2 and the *1/*2 heterozygotes having an intermediate value, suggesting enhanced in vivo P-glycoprotein activity among subjects with the MDR1*2 allele. fexofenadine 74-86 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 10421612-9 1999 Because OATP transporters and P-gp colocalize in organs of importance to drug disposition such as the liver, their activity provides an explanation for the heretofore unknown mechanism(s) responsible for fexofenadine"s disposition and suggests potentially similar roles in the disposition of other xenobiotics. fexofenadine 204-216 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 33825113-1 2021 PURPOSE: Fexofenadine is a well-identified in vivo probe substrate of P-glycoprotein (P-gp) and/or organic anion transporting polypeptide (OATP). fexofenadine 9-21 ATP binding cassette subfamily B member 1 Homo sapiens 70-84 33825113-1 2021 PURPOSE: Fexofenadine is a well-identified in vivo probe substrate of P-glycoprotein (P-gp) and/or organic anion transporting polypeptide (OATP). fexofenadine 9-21 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 33825113-2 2021 This work aimed to investigate the transplacental pharmacokinetics of fexofenadine enantiomers with and without the selective P-gp inhibitor fluoxetine. fexofenadine 70-82 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 33832418-5 2021 The transport of the P-gp substrate fexofenadine was evaluated in a special Transwell system. fexofenadine 36-48 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 33256506-0 2021 Effects of Breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. fexofenadine 85-97 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 33256506-0 2021 Effects of Breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. fexofenadine 85-97 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 33256506-4 2021 The aim of this study was to evaluate the effect of BRE on the pharmacokinetics of fexofenadine, a P-gp probe substrate and its associations with the MDR1 C3435T genetic polymorphism in healthy volunteers. fexofenadine 83-95 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 33256506-4 2021 The aim of this study was to evaluate the effect of BRE on the pharmacokinetics of fexofenadine, a P-gp probe substrate and its associations with the MDR1 C3435T genetic polymorphism in healthy volunteers. fexofenadine 83-95 ATP binding cassette subfamily B member 1 Homo sapiens 150-154 33372901-2 2020 Pgp activity was analyzed in a transwell system by the transport of its substrate, fexofenadine. fexofenadine 83-95 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 32557079-2 2020 Fexofenadine, an in vivo P-gp probe, is an antihistamine drug for seasonal allergic rhinitis and chronic urticaria treatment during pregnancy and it is available as a racemic mixture. fexofenadine 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 32557079-10 2020 CONCLUSIONS: A single oral dose of 40 mg fluoxetine inhibited the intestinal P-gp mediated transport of S-(-)-fexofenadine to a greater extent than R-(+)-fexofenadine in parturient women. fexofenadine 104-122 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 28090646-0 2017 Influence of P-glycoprotein on the disposition of fexofenadine and its enantiomers. fexofenadine 50-62 ATP binding cassette subfamily B member 1 Homo sapiens 13-27 31581637-4 2019 As part of a study evaluating potential drug-drug interactions between probe drugs of the Geneva cocktail, the present paper focuses on the impact of cytochromes (CYP) probe drugs on the disposition of fexofenadine, a P-gp test drug. fexofenadine 202-214 ATP binding cassette subfamily B member 1 Homo sapiens 218-222 30280663-2 2019 This guidance has indicated that digoxin, dabigatran etexilate and fexofenadine are P-gp substrate drugs and has defined P-gp inhibitors as those that increase the AUC of digoxin by 1.25-fold in clinical DDI studies. fexofenadine 67-79 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 30280663-2 2019 This guidance has indicated that digoxin, dabigatran etexilate and fexofenadine are P-gp substrate drugs and has defined P-gp inhibitors as those that increase the AUC of digoxin by 1.25-fold in clinical DDI studies. fexofenadine 67-79 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 30020547-1 2018 Thirty-two Collies were used to determine the impact of ABCB1 genotype and phenotype on the plasma pharmacokinetics of fexofenadine"s (Fex) R- and S-enantiomers after bolus Fex administration, as human P-gp exhibits stereoselectivity. fexofenadine 119-131 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 29635947-7 2018 P-gp inducers, carbamazepine, and inhibitors such as itraconazole and verapamil show greater effects on the pharmacokinetics of (S)-fexofenadine. fexofenadine 128-144 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 29635947-10 2018 Combinations of multiple transporters such as OATP2B1 and P-gp facilitate enantioselective disposition of fexofenadine. fexofenadine 106-118 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 27981349-0 2017 The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. fexofenadine 53-65 ATP binding cassette subfamily B member 1 Homo sapiens 69-83 27981349-2 2017 The aim of this study was to evaluate the effect of PIP on the pharmacokinetics of fexofenadine (FEX), a P-gp substrate, in healthy volunteers. fexofenadine 83-95 ATP binding cassette subfamily B member 1 Homo sapiens 105-109 27981349-2 2017 The aim of this study was to evaluate the effect of PIP on the pharmacokinetics of fexofenadine (FEX), a P-gp substrate, in healthy volunteers. fexofenadine 97-100 ATP binding cassette subfamily B member 1 Homo sapiens 105-109 30280663-4 2019 OBJECTIVE: Since there are no detailed manuscripts that summarizes P-gp interactions unrelated to CYP metabolism, this article reviews the effects of potent P-gp inhibitors and P-gp inducers on the pharmacokinetics of P-gp substrate drugs, including digoxin, talinolol, dabigatran etexilate, and fexofenadine in human studies. fexofenadine 296-308 ATP binding cassette subfamily B member 1 Homo sapiens 157-161 30280663-4 2019 OBJECTIVE: Since there are no detailed manuscripts that summarizes P-gp interactions unrelated to CYP metabolism, this article reviews the effects of potent P-gp inhibitors and P-gp inducers on the pharmacokinetics of P-gp substrate drugs, including digoxin, talinolol, dabigatran etexilate, and fexofenadine in human studies. fexofenadine 296-308 ATP binding cassette subfamily B member 1 Homo sapiens 157-161 30280663-4 2019 OBJECTIVE: Since there are no detailed manuscripts that summarizes P-gp interactions unrelated to CYP metabolism, this article reviews the effects of potent P-gp inhibitors and P-gp inducers on the pharmacokinetics of P-gp substrate drugs, including digoxin, talinolol, dabigatran etexilate, and fexofenadine in human studies. fexofenadine 296-308 ATP binding cassette subfamily B member 1 Homo sapiens 157-161 28301431-5 2017 In addition, oral fexofenadine was used as an in vivo probe for P-gp activity. fexofenadine 18-30 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 28090646-3 2017 Using fexofenadine as a model compound, we developed and validated HPLC-fluorescence methods to determine the effect of P-gp on the disposition of fexofenadine and its enantiomers. fexofenadine 6-18 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 28090646-3 2017 Using fexofenadine as a model compound, we developed and validated HPLC-fluorescence methods to determine the effect of P-gp on the disposition of fexofenadine and its enantiomers. fexofenadine 147-159 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 28090646-8 2017 KEY FINDINGS: This study demonstrates that P-gp prefers to transport (S)-fexofenadine, and P-gp deficiency causes the increase in both (R)-fexofenadine and (S)-fexofenadine in plasma. fexofenadine 69-85 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 28090646-8 2017 KEY FINDINGS: This study demonstrates that P-gp prefers to transport (S)-fexofenadine, and P-gp deficiency causes the increase in both (R)-fexofenadine and (S)-fexofenadine in plasma. fexofenadine 156-172 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 28090646-9 2017 Racemic fexofenadine, (R)-fexofenadine and (S)-fexofenadine were increased in ABCB1-1Delta Collies (118.7, 72.0 and 48.3 ng/ml) compared to wild-type Collies (25.0, 16.5 and 7.7 ng/ml) at 1 h postadministration. fexofenadine 8-20 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 28090646-9 2017 Racemic fexofenadine, (R)-fexofenadine and (S)-fexofenadine were increased in ABCB1-1Delta Collies (118.7, 72.0 and 48.3 ng/ml) compared to wild-type Collies (25.0, 16.5 and 7.7 ng/ml) at 1 h postadministration. fexofenadine 43-59 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 28090646-10 2017 The results demonstrate that the stereoselectivity of P-gp plays a key role in the disposition of fexofenadine enantiomers. fexofenadine 98-110 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 26467209-0 2016 Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites. fexofenadine 142-154 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 25908246-9 2015 OATP1A2 counteracted P-gp efflux for cosubstrates zolmitriptan and fexofenadine. fexofenadine 67-79 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 25953731-0 2015 Design of Fexofenadine Prodrugs Based on Tissue-Specific Esterase Activity and Their Dissimilar Recognition by P-Glycoprotein. fexofenadine 10-22 ATP binding cassette subfamily B member 1 Homo sapiens 111-125 23422332-7 2013 Fexofenadine was used as a P-gp phenotyping probe. fexofenadine 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 25759055-7 2015 The findings suggested that a combination of multiple transporters involving organic anion transporting polypeptide (OATP) 2B1, P-glycoprotein (P-gp), and multidrug resistance-associated protein 2 (MRP2) react to stereoselective fexofenadine exposure. fexofenadine 229-241 ATP binding cassette subfamily B member 1 Homo sapiens 128-142 25759055-7 2015 The findings suggested that a combination of multiple transporters involving organic anion transporting polypeptide (OATP) 2B1, P-glycoprotein (P-gp), and multidrug resistance-associated protein 2 (MRP2) react to stereoselective fexofenadine exposure. fexofenadine 229-241 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 25759055-9 2015 Coadministration of P-gp inducer/inhibitors significantly altered the pharmacokinetics of fexofenadine enantiomers. fexofenadine 90-102 ATP binding cassette subfamily B member 1 Homo sapiens 20-24 25759055-12 2015 Taken together, these studies indicated that multiple transporters including P-gp, OATPs, and MRP2 play important roles in fexofenadine enantiomer pharmacokinetics. fexofenadine 123-135 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 24040855-0 2013 The role of multidrug resistance-1 (MDR1) variants in response to fexofenadine among Jordanians. fexofenadine 66-78 ATP binding cassette subfamily B member 1 Homo sapiens 12-34 24040855-0 2013 The role of multidrug resistance-1 (MDR1) variants in response to fexofenadine among Jordanians. fexofenadine 66-78 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 24040855-2 2013 The P-gp has wide substrate specificity for multiple medications, including the antiallergic drug fexofenadine. fexofenadine 98-110 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 24040855-3 2013 In this study, we investigated the possible association between three common MDR1 gene polymorphisms (G2677T, C3435T, and C1236T), and the anti-allergic effect of fexofenadine among Jordanians. fexofenadine 163-175 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 24040855-11 2013 CONCLUSIONS: The MDR1 gene polymorphism C1236T was associated with the anti-allergic effect of fexofenadine among male Jordanians. fexofenadine 95-107 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 25263393-10 2015 Therefore, the interactive mechanism of multidose rifampicin may occur through a combination of OATP and P-gp transporters, thereby altering the pharmacokinetics of fexofenadine enantiomers. fexofenadine 165-177 ATP binding cassette subfamily B member 1 Homo sapiens 105-109 24423593-2 2014 P-gp (fexofenadine) and CYP-specific substrates (caffeine for CYP1A2, bupropion for CYP2B6, flurbiprofen for CYP2C9, omeprazole for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4) and their metabolites were extracted from DBS (10 microl) using methanol. fexofenadine 6-18 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 23422332-15 2013 In the placebo phase, T1/2 of fexofenadine in ABCB1 3435T mutation allele carriers was longer compared to ABCB1 3435CC carriers (4.43+-1.44h vs. 2.54+-0.21h, p<0.05). fexofenadine 30-42 ATP binding cassette subfamily B member 1 Homo sapiens 46-51 21646440-2 2012 The purpose of this study was to determine the influence of Panax ginseng on CYP3A and P-gp function using the probe substrates midazolam and fexofenadine, respectively. fexofenadine 142-154 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 23115085-9 2013 In conclusion, rifampicin has multiple interaction sites with fexofenadine, all of which contribute to increasing the area under the curve of fexofenadine when they are given simultaneously, to surpass the effect of the induction of P-glycoprotein elicited by multiple doses. fexofenadine 62-74 ATP binding cassette subfamily B member 1 Homo sapiens 233-247 21950458-1 2012 AIM: This aim of this study was to characterize the impact of the P-glycoprotein (P-gp) inducer, carbamazepine, on fexofenadine enantiomer pharmacokinetics. fexofenadine 115-127 ATP binding cassette subfamily B member 1 Homo sapiens 66-80 21950458-1 2012 AIM: This aim of this study was to characterize the impact of the P-glycoprotein (P-gp) inducer, carbamazepine, on fexofenadine enantiomer pharmacokinetics. fexofenadine 115-127 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 21950458-5 2012 The P-gp inducer showed a greater effect on the pharmacokinetic parameters of (S)-fexofenadine. fexofenadine 78-94 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 22198458-4 2012 Multiple-dose ketoconazole coadministration reduced the P-gp activity as shown by fexofenadine oral challenge. fexofenadine 82-94 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 21039758-2 2010 The discovery was based on an opposite to anticipated finding when assessing the possibility of grapefruit juice increasing oral fexofenadine bioavailability in humans through inhibition of intestinal MDR1-mediated efflux transport. fexofenadine 129-141 ATP binding cassette subfamily B member 1 Homo sapiens 201-205 20214407-4 2010 Digoxin, fexofenadine, talinolol and quinidine are commonly used probe drugs for P-gp phenotyping. fexofenadine 9-21 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 20839930-4 2010 The pharmacokinetic properties of S-fexofenadine are affected by a single polymorphism of SLCO2B1 in combination with several polymorphisms of ABCB1 C1236T, C3435T, and ABCC2 C-24T. fexofenadine 34-48 ATP binding cassette subfamily B member 1 Homo sapiens 143-148 20839930-6 2010 These findings suggest that a combination of multiple transporters, including OATP, P-gp, and MRP2, reacts strongly to fexofenadine exposure in the small intestine and liver, resulting in different dispositions of both enantiomers. fexofenadine 119-131 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 20306185-0 2010 Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. fexofenadine 51-63 ATP binding cassette subfamily B member 1 Homo sapiens 67-81 20306185-3 2010 We have assessed the possible inhibitory effects of metronidazole on P-gp-mediated drug disposition in healthy subjects using fexofenadine as a P-gp substrate. fexofenadine 126-138 ATP binding cassette subfamily B member 1 Homo sapiens 144-148